Efficacy, Safety and Immunogenicity of Insulin Aspart Biosimilar SAR341402 Compared with Originator Insulin Aspart in Adults with Diabetes (GEMELLI 1): A Subgroup Analysis by Prior Type of Mealtime Insulin
mediaposted on 2021-01-06, 14:32 authored by Viral N. Shah, Edward Franek, Karin Wernicke-Panten, Suzanne Pierre, Bhaswati Mukherjee, Karita Sadeharju
Article full text
The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2021.